Name | Sembragiline |
---|---|
Synonyms |
K3W9672PNJ
UNII-K3W9672PNJ Acetamide, N-[(3S)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxo-3-pyrrolidinyl]- RG1577 Sembragiline N-[(3S)-1-{4-[(3-Fluorobenzyl)oxy]phenyl}-5-oxo-3-pyrrolidinyl]acetamide MFCD28963964 |
Description | Sembragiline (RO4602522, RG1577, EVT 302) is a novel potent, selective, orally available monoamine oxidase B (MAO-B) inhibitor with IC50 of 5.9 nM, >600-fold selectivity over MAO-A; displays no affinity for more than 100 different receptors, enzymes and ion channels; protects against neuronal loss and reduces both ROS formation and reactive astrogliosis in transgenic animal model conditionally overexpressing MAO-B in astroglia, exhibits potential for treatment of Alzheimer's disease (AD) and other neurodegenerative disorders. Alzheimer Disease Phase 2 Clinical |
---|---|
References | References 1. Borroni E, et al. J Pharmacol Exp Ther. 2017 Sep;362(3):413-423. 2. Nave S, et al. J Alzheimers Dis. 2017;58(4):1217-1228. 3. Yeon SK, et al. Bioorg Med Chem. 2018 Jan 1;26(1):232-244. View Related Products by Target Monoamine Oxidase (MAO) Alzheimer Disease |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 644.4±55.0 °C at 760 mmHg |
Molecular Formula | C19H19FN2O3 |
Molecular Weight | 342.364 |
Flash Point | 343.5±31.5 °C |
Exact Mass | 342.137970 |
LogP | 1.49 |
Vapour Pressure | 0.0±1.9 mmHg at 25°C |
Index of Refraction | 1.607 |